Physician profile
Azeem A Mohammed
NPI 1124258843
$1,380.34
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $232 · 2021: $253 · 2022: $251 · 2023: $181 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $455.60 | 2019-2022 | |
| Ucb, INC. | $134.85 | 2022-2024 | Cimzia |
| Abbvie INC. | $130.34 | 2021-2024 | |
| Novo Nordisk INC | $98.22 | 2021-2023 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $72.31 | 2019-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $72.01 | 2020-2021 | |
| Glaxosmithkline, LLC. | $48.40 | 2022-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $36.65 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $35.87 | 2023 | Lupkynis |
| Dexcom, INC. | $34.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.59 | 2021 | |
| Amgen INC. | $33.44 | 2019-2022 | |
| Vifor Pharma, INC. | $32.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.50 | 2019 | |
| Akebia Therapeutics INC | $22.55 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.91 | 2023 | Omnipod |
| Pfizer INC. | $18.27 | 2021 | |
| Janssen Biotech, INC. | $17.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2022 | |
| Calliditas Therapeutics US INC. | $15.62 | 2023 | Tarpeyo |
| Allergan, INC. | $14.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeem Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.